Aktuellt
SENASTE
Redeye's provides its initial take on Oncopeptides’ year-end report, which came in slightly softer than we had estimated, albeit still showing growth in Pepaxti sales and progress in licensing discussions. We anticipate making moderate revisions to our financial projections and fair value range.
LÄS MER
